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Abstract
Background: Acute respiratory distress syndrome (ARDS) induced by pandemic 2009 H1N1 influenza virus has been widely
reported and was considered the main cause of death in critically ill patients with 2009 H1N1 infection. However, no animal
model has been developed for ARDS caused by infection with 2009 H1N1 virus. Here, we present a mouse model of ARDS
induced by 2009 H1N1 virus.
Methodology Principal Findings: Mice were inoculated with A/swine/Shandong/731/2009 (SD/09), which was a 2009 H1N1
influenza variant with a G222D mutation in the hemagglutinin. Clinical symptoms were recorded every day. Lung injury was
assessed by lung water content and histopathological observation. Arterial blood gas, leukocyte count in the bronchial
alveolar lavage fluid and blood, virus titers, and cytokine levels in the lung were measured at various times post-inoculation.
Mice infected with SD/09 virus showed typical ARDS symptoms characterized by 60% lethality on days 8–10 post-
inoculation, highly edematous lungs, inflammatory cellular infiltration, alveolar and interstitial edema, lung hemorrhage,
progressive and severe hypoxemia, and elevated levels of proinflammatory cytokines and chemokines.
Conclusions/Significance: These results suggested that we successfully established an ARDS mouse model induced by a
virulent 2009 H1N1 variant without previous adaptation, which may be of benefit for evaluating the pathogenesis or
therapy of human ARDS caused by 2009 H1N1 virus.
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Introduction
A novel influenza A (H1N1) virus of swine origin emerged
among humans in Mexico during the spring of 2009 and rapidly
spread worldwide [1]. The pandemic prompted the World Health
Organization (WHO) to raise the alert level to the highest rating of
six, the pandemic phase, within 2 months [2]. In August 2010,
WHO officially declared that the disease was in the post-pandemic
period [3]; however, it is still circulating among humans, together
with seasonal viruses. Although most influenza cases caused by
2009 H1N1 virus infection typically display mild upper respiratory
tract syndrome, some cases progress to severe pneumonia and
acute respiratory distress syndrome (ARDS) [4,5]. Many studies
have shown that ARDS caused by 2009 H1N1 virus results in
17.3–56% mortality [4,6,7,8], which was regarded as the major
cause of death by 2009 H1N1 virus infection [9]. ARDS is the
result of acute injury to lung tissue, commonly resulting from
sepsis, trauma, and severe pulmonary infections [10]. Infectious
factors, most of which are viruses, have become one of the most
important causes of ARDS in humans [11,12,13]. Clinical cases
and established animal models have revealed that the pathogenesis
and pathological features of ARDS induced by different viral
pathogens are distinct [14,15]. However, knowledge of the
pathogenesis of 2009 H1N1 virus, especially ARDS induced by
2009 H1N1 virus, is still limited and hinders therapeutic strategies.
Therefore, it is necessary to evaluate the pathogenesis of ARDS
caused by 2009 H1N1 virus infection in an appropriate animal
model to assess potential therapies.
Mice are a good model for evaluating the pathogenesis and
antiviral therapy of influenza pneumonia, due to the general
fidelity of the illness in mice to the human disease [16]. Moreover,
a mouse model of ARDS caused by highly pathogenic H5N1
avian influenza virus infection has been well established [13]. The
typical 2009 H1N1 virus, such as A/California/04/2009 (CA/04),
can efficiently replicate in mouse lungs without prior host
adaptation. However, it only causes moderate lung lesions and
no mortality, even when inoculated at a high dose of 10
6 pfu
[17,18]. Thus, such typical 2009 H1N1 viruses may not be able to
induce ARDS in a mouse model.
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29347In the present study, we used a virulent variant 2009 H1N1
virus, which was isolated from a pig and possessed a virulence-
associated HA-D222G mutation, to establish an ARDS mouse
model. The model established here provides a useful tool to
explore the mechanism of ARDS, as well as screening and
therapeutic options.
Results
Clinical and gross pathologic observation
Six-week-old female mice were infected intranasally (i.n.) with
10
2.5 pfu SD/09 virus. Some of the infected mice showed signs of
illness, such as altered gait, inactivity, ruffled fur, and anorexia on
day 2 post-infection (p.i.). From day 2 p.i., the body weight of most
mice significantly decreased (Figure S1). By day 6 p.i., most mice
presented with more severe clinical signs of respiratory disease,
including labored respiration and respiratory distress, and most
mice lost almost 20% of their initial body weight. On day 8 p.i.,
most mice were nearly unable to respond to exterior stimuli, and
acute respiratory rates and labored respiration were observed
(Video S1, and Video S2 for control). Approximately 60% of mice
died between days 8 and 10 p.i. Gross observation of infected mice
showed that the lungs were highly edematous, with profuse areas
of hemorrhage and consolidation. No obvious gross lesions were
observed in the kidneys, liver, spleen or brain of infected mice.
Replication kinetics of SD/09 virus in mouse tissues
Mice were infected i.n. with 10
2.5 pfu SD/09 virus, and three
mice were euthanized on days 2, 4, 6, 8, 10 and 14 p.i., and the
virus titers in viscera were determined. As shown in Figure 1A, the
virus titer in the lung gradually increased between days 2 and 6
p.i., and reached a peak on day 6 p.i. The virus titers in the lung
gradually decreased from day 6 p.i., and only one of three mice
possessed detectable virus in the lungs on day 10 p.i. No viruses
were detected in other organs, including heart, spleen, liver,
kidneys, blood and brain, at the indicated time. These results
indicate that SD/09 virus could replicate efficiently in mouse lung
but did not cause systemic infection.
Lung edema induced by SD/09 virus
As shown in Figure 1B, the effect of SD/09 viral infection on
lung wet:dry weight ratio did not change significantly within 2
days p.i. However, a dramatic increase was observed from day 4
p.i., and reached a peak on day 8 p.i., which was nearly twice that
observed in control group lungs (p,0.01). The change in lung wet
weight:body weight ratio was similar to the change in lung wet:dry
weight ratio (Figure 1C). The results indicated that the SD/09
virus could induce acute lung edema in mice.
Histopathology and immunohistochemistry
Kinetic observation of lung lesions of SD/09-virus-infected mice
is shown in Figure 2. On day 4 p.i., lung lesions were characterized
by dropout of mucous epithelium and inflammatory cells adhering
to the bronchiolar surface (Figure 2C, D). On day 6 p.i., severe
edema could be seen around blood vessels (Figure 2E); interstitial
pneumonia was also observed that showed interstitial edema and
thickening of the alveolar walls; and the alveolar lumen was
flooded with detached alveolar cells, erythrocytes, and inflamma-
tory cells (Figure 2E, F). On day 8 p.i., the virus caused more
severe interstitial pneumonia and peribronchiolitis, characterized
by edema and extensive of lymphocytes, neutrophils and plasma
cells around the area of bronchiolitis (Figure 2G, H). Lesions in the
lungs of infected mice were still severe on day 14 p.i., with
extensive alveolar collapse, and remaining alveoli were filled with
fibrin, desquamated alveolar cells, and inflammatory cells.
Lymphocytes and alveolar macrophages were the predominant
inflammatory cells observed at high magnification (Figure 2J).
Masson’s stain revealed that alveolar walls and spaces were filled
with collagen fibers (Figure 3A, B), indicating that proliferative
fibroblastic lesions may develop. In comparison, lungs from mock-
infected control mice had no apparent histological changes
(Figure 2A, 2B, 3C).
Figure 1. Virus titers in lung (A), wet:dry weight ratio (B) and
wet weight:body weight ratios (C) of SD/09-infected mice. Mice
were inoculated i.n. with 10
2.5 pfu SD/09 viruses; tissues were collected
at indicated times p.i. and viruses were titrated in MDCK cells. Body
weight, lung wet and dry weight were determined and recorded. The
lung wet weight:body weight ratio and lung wet:dry weight ratio were
calculated and used as an indicator of lung edema. *p,0.05, **p,0.01,
***p,0.001, comparison between ratios obtained from the virus-
infected and control groups. Bars represent means 6 SD of data from
three mice.
doi:10.1371/journal.pone.0029347.g001
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PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29347Figure 2. Hematoxylin-eosin stained sections from lung tissues of SD/09-infected mice. Normal mouse lungs (A, B). On day 4 p.i., dropout
of mucous epithelium and inflammatory cells adhered to the surface of bronchioles (C, D, solid arrows). On day 6 p.i., severe edema around blood
vessels (E, open arrows); dropout of alveolar epithelial, erythrocytes, and inflammatory cells within alveolar spaces (E, F, D). On day 8 p.i., the virus
caused more severe interstitial pneumonia (G, H, D), bronchiolitis (G, H, solid arrows) and peribronchiolitis (G, H, open arrows). On day 14 p.i., the
interstitial tissue was thickened with fibrin exudation and organization (I, D). Lymphocytes and alveolar macrophages were the predominant
inflammatory cells observed (J, solid arrows). Magnification: C, E, G, and I, 6100; A, D and H, 6200; B, F and J, 6400.
doi:10.1371/journal.pone.0029347.g002
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cells of the bronchioles (Figure 3D), terminal bronchioles, and
alveolar epithelial cells (Figure 3E). These data indicated that SD/
09 virus could infect the epithelia of the lower airway and cause
viral pneumonia in mice.
Arterial blood gas analysis
As shown in Table 1, virus-infected mice showed a slightly
decreased partial pressure of arterial oxygen (PaO2), saturation of
arterial oxygen (SaO2), and slightly increased partial pressure of
arterial carbon dioxide (PaCO2) from days 4 to 6 p.i. Most infected
mice presented with severe clinical signs of respiratory distress on
day 8 p.i., and blood gas analysis also showed that PaO2 and SaO2
dramatically decreased compared with the controls (p,0.05).
These results suggested acute respiratory dysfunction and severe
hypoxemia in virus-infected mice.
Leukocyte counts in Bronchial Alveolar Lavage Fluid (BALF)
The number of leukocytes in BALF from SD/09-infected mice
showed an increase from day 4 p.i. (Table 2). The BALF of virus-
infected mice on day 6 p.i contained 1.1610
6 cells/ml and was
significantly different from the 1.6610
5 cells/ml observed for PBS-
inoculated mice (p,0.001). These data indicate a dramatic increase in
inflammatory cells in the lungs of SD/09-infected mice. To quantify
the immune cell subpopulations responding to viral infection, we next
determined cell differential counts in the infected lungs by Wright
staining. Compared with PBS-inoculated animals, mice infected with
SD/09 virus exhibited an increase of neutrophils from 4 days p.i., and
the peak was 18-fold greater than that of the control group on day 8 p.i.
Peripheral blood leukocyte counts
Figure 4A shows a progressive reduction in the number of
leukocytes observed on days 4–10 p.i. in virus-infected mice.
Figure 3. Masson’s trichrome stained sections (A–C) and immunohistochemical staining for influenza A nucleoprotein (D–F) of the
SD/09-infected mouse lung. Alveoli were collapsed and filled with collagen fibers (A, B, open arrows); normal mouse lungs (C). Influenza A
nucleoprotein (brown) in the epithelial cells of the bronchioles (D, solid arrows); viral nucleoprotein in abundant terminal bronchioles epithelial cells
and few alveolar epithelial cells (E, solid arrows); normal mouse lungs (F). Magnification: A, 6100; B, C, D, E and F, 6400.
doi:10.1371/journal.pone.0029347.g003
Table 1. Arterial blood gas analysis.
Time (d) PaO2 (mmHg) PaCO2 (mmHg) SaO2 (%)
H1N1 Control H1N1 Control H1N1 Control
48 2 . 0 0 61.41 93.0069.65 35.0065.65 29.5063.54 91.0061.41 91.5062.12
67 4 . 5 0 62.12 91.0061.41 41.0065.65 30.7563.18 86.5062.12 91.0062.83
85 7 . 5 0 63.54* 90.5063.54 52.5064.95* 28.5062.83 78.5063.54** 91.5060.71
10 73.00612.72 89.5062.12 43.0064.24 29.2562.47 83.5063.54 89.0064.24
14 71.50612.02 91.5063.54 39.50613.44 31.5066.36 85.5063.54 91.5062.12
Mice were inoculated i.n. with 10
2.5 pfu SD/09 viruses. Arterial blood samples were collected at indicated times p.i.
Values are expressed as mean 6 SD.
*p,0.05,
**p,0.01, comparison between virus-infected and control groups.
doi:10.1371/journal.pone.0029347.t001
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significant on day 6 p.i. (p,0.05); the lowest value appeared on
day 8 p.i. (p,0.001). Furthermore, differential blood counts
revealed that the number of lymphocytes sharply decreased in
infected mice. The lowest number of lymphocytes observed
occurred on day 8 p.i. (Figure 4B), which dropped to ,20% of
the control group number (p,0.001).
Cytokine production following SD/09 infection
To determine the cytokine responses that occur after SD/09
virus infection, we measured the levels of five cytokines and
chemokines in lungs of infected mice on days 2, 4, 6, 8 and 10 p.i.
As shown in Figure 5, all five were significantly different between
virus-infected and control mice. Interleukin (IL)-6 and IL-10 in the
virus-infected mice reached peak levels as early as day 2 p.i. and
were significantly higher than those of the control group
(p,0.001). Interferon (IFN)-c, monocyte chemotactic protein
(MCP)-1, and tumor necrosis factor (TNF) dramatically increased
in mouse lungs on days 6–8 p.i. (p,0.001), consistent with the
appearance of pulmonary lesions. These results showed that
infection with SD/09 viruses resulted in elevated amounts of
proinflammatory chemokines and cytokines in the lungs of mice.
Discussion
In the spring of 2009, a novel influenza A(H1N1) virus rapidly
spread worldwide, resulting in the first influenza pandemic of the
21st century [1]. Critically ill cases caused by 2009 H1N1 virus
retrospectively showed that most had progressed or died due to
ARDS [4,6]. However, the pathogenesis and therapeutic inter-
vention of ARDS caused by 2009 H1N1 infection have still not
been elucidated. Animal models of disease are important for
characterizing pathogenesis and developing the preclinical evi-
dence for revised approaches to ventilating patients with ARDS
[19]. Here, we present a mouse model for the study of ARDS
induced by SD/09 virus, a virulent 2009 H1N1 variant.
Previous studies have indicated that typical 2009 H1N1 viruses
such as CA/04 bind only to a-2,6-linked sialic acid (SA) receptor
Table 2. White blood cell (WBC) summary and differential counts in BALF.
Time (d) WBC Summary (1610
5) WBC count %
Macrophages Lymphocytes Neutrophils
4 H1N1 3.9260.14 55.1666.80
* 38.2665.60
* 3.6960.89
**
Control 1.5760.26 89.3866.21 8.6261.25 0.6860.21
6 H1N1 10.7565.62
*** 31.6662.39
** 49.4466.26
** 12.7262.77
***
Control 1.4960.29 90.6562.71 6.9762.25 0.6960.35
8 H1N1 9.1662.21
** 26.6362.19
** 40.463.22
** 28.9361.98
***
Control 1.8560.59 88.6664.34 7.6561.20 1.5860.48
10 H1N1 8.5962.81
** 33.2362.70
** 42.2564.42
** 21.6267.90
***
Control 1.6960.48 89.3264.8 6.9361.2 0.9960.37
Mice were inoculated i.n. with 10
2.5 pfu SD/09 viruses, and BALF was prepared at indicated times p.i.
Values are expressed as mean 6 SD.
*p,0.05.
**, p,0.01,
***p,0.001, comparison between virus-infected and control groups.
doi:10.1371/journal.pone.0029347.t002
Figure 4. Kinetic analysis of circulating leukocytes (A) and lymphocyte (B) following SD/09 virus infection. Peripheral blood samples
were collected at indicated times p.i. The total number of leukocytes and differential blood counts for three individual mice were analyzed. *p,0.05
**, p,0.01, ***p,0.001, comparison between virus-infected and control groups.
doi:10.1371/journal.pone.0029347.g004
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respiratory tract [20]. Therefore, such a typical 2009 H1N1 virus
may not be able to induce ARDS in mice. In fact, we used CA/04
virus to induce ARDS in mice; however, animals inoculated with a
high dose of CA/04 virus (10
6.5 pfu) only showed moderate
respiratory symptoms, and no lethality was observed (unpublished
Figure 5. Cytokine levels in virus-infected mouse lungs. Mice were euthanized at indicated times p.i. The collected lungs were weighed, and
10% homogenates were prepared in cold PBS. Cytokine levels from lung homogenates were measured using the Cytokine Bead Array system.
*p,0.05, **p,0.01, ***p,0.001, comparison between virus-infected and control groups.
doi:10.1371/journal.pone.0029347.g005
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D222G mutation in hemagglutinin (HA) could increase the
pathogenicity in mice [21,22] and binding to the a-2,3 SA
receptor [23]. Moreover, clinical data indicate that such variants
are only associated with severe H1N1 human infection [24].
Therefore, we suggest that the variant possessing the D222G
mutation in HA can induce ARDS in a mouse model. The virus
used in the present study was isolated from swine in 2009, and
sequence analysis revealed that all the eight genes of the isolate
had a close relationship with the 2009 H1N1 influenza virus
circulating in humans. Notably, the swine isolate, SD/09, had a
D222G mutation in HA. Compared with CA/04 virus (LD50.10
6
pfu), SD/09 showed significantly increased virulence in mice,
with an LD50 of 10
2.25 pfu, which was nearly identical to that
of the mouse-adapted strain A/Hong Kong/415742Md/09
(LD50=10
2.2pfu) [17,21]. Mice infected i.n. with 10
2.5 pfu SD/
09 virus showed obvious respiratory symptoms, including visually
prominent signs of respiratory distress and abdominal respiration,
with approximately 60% mortality between days 8 and 10 p.i. The
lungs of virus-infected mice were highly edematous, which was
also demonstrated by dramatically increased lung wet:dry weight
ratio. Pathological changes presented a progressive pattern,
typically diffuse alveolar damage, interstitial and alveolar edema,
neutrophil and macrophage-dominant inflammatory cellular
infiltration, and areas of hemorrhage and necrotizing bronchiolitis.
Arterial blood gas saturation is a key parameter of ARDS in
humans [25]. In the present mouse model, Pao2 and Sao2 of
infected mice were significantly lower than in the control group
from day 2 p.i., especially on day 8 p.i., where these parameters
sharply decreased, and most virus-infected mice began to die.
These changes in arterial blood gas demonstrated that most
infected mice developed severe hypoxemia consistent with of the
appearance of clinical signs and lung lesions of ARDS.
Previous studies showed that mice infected with typical 2009
H1N1 virus only exhibited mild interstitial inflammatory infiltra-
tion and limited alveolitis [18,21], whereas severe lung damage
was found in the SD/09-infected mice, including severe edema
around the blood vessels and bronchiolitis, and extensive
inflammatory accumulation from 4 to 8 days p.i. At 10 days p.i.,
the surviving mice developed an irreversible fibrosis involving
collagen deposition in alveolar walls and spaces, which was similar
to that observed in human ARDS patients with 2009 H1N1
infection [26]. Our histopathological results were consistent with
ARDS induced by other influenza viruses. Mice infected with
mouse-adapted virus of the A/Puerto Rico/8/34 (H1N1), or high
pathogenic H5N1 virus also showed a progressive series of
pathological changes from interstitial pneumonia to diffuse
alveolar damage [13,27]. However, in contrast to highly
pathogenic H5N1 virus, mice infected with SD/09 virus did not
show viral spread to extrapulmonary organs.
Immunohistochemical examination revealed the presence of
viral antigens in the bronchioles, terminal bronchiolar epithelium,
and alveolar epithelial cells. Perhaps SD/09 virus infection of the
alveoli, particularly type II pneumocytes, rather than bronchioles,
is a key to the development of ARDS. Type II pneumocytes are
responsible for the production and secretion of surfactant to lower
the surface tension of water and allow membrane separation, and
insufficient pulmonary surfactant in the alveoli may result in
alveolar collapse [28,29]. The 1918 pandemic H1N1 and high
pathogenic H5N1 viruses preferentially infect type II pneumocytes
and alveolar macrophage in mice [15,30]. Alveolar macrophages
may play a critical role in disease pathogenesis, not through
production of infectious virus but rather through the upregulation
of proinflammatory cytokines that may further damage alveolar
pneumocytes [31]. These phenomena suggest that viral cell
tropism may determine the processes of ARDS.
Pulmonary aberrant immune response is considered a signifi-
cant feature of ARDS induced by 2009 H1N1 virus [19,32]. In the
present mouse model, the number of leukocytes observed in the
BALF of virus-infected mice significantly increased compared with
the control mice on day 8 p.i. Different counts in BALF showed
that the proportion of neutrophils dramatically increased. These
innate immune cells were capable of reducing the virus load in the
lung [33]; however, they could cause lung injury through direct or
indirect mechanisms. Neutrophil oxidants and proteases can cause
direct injury of cells in the alveolar-capillary membrane [34].
Neutrophils and macrophages can secrete copious amounts of
chemokines and cytokines that can recruit more immune cells into
lung tissues, and produce a ‘‘cytokine storm’’, one of the most
important factors in the production of ARDS [35].
A retrospective cohort study of 74 2009 H1N1 patients found
that higher levels of proinflammatory cytokines and chemokines in
plasma were observed in the ARDS-death group compared with
the survived-without-ARDS or the mild-disease groups [5].
Another study in critically ill patients with ARDS caused by
2009 H1N1 virus infection has shown that the hallmarks of disease
severity were elevated levels of IL-6, IL-15, IL-8 and TNF-a [36].
We examined the levels of five cytokines and chemokines in
infected mouse lungs and found significant differences between the
virus-infected and mock groups. It has proved that high levels of
IL-6 were able to mediate acute lung injury [37], and had a
negative correlation with the PaO2:FiO2 ratio in severely affected
patients with 2009 H1N1 virus infection [36]. Our data showed
SD/09 viral infection induced high levels of IL-6 in mouse lung,
which may also play an important role in the course of ARDS.
Hagau etc. found the levels of TNF-a increased significantly in the
2009 H1N1-related ARDS patients [36]. In present study, TNF
levels also dramatically increased in the lungs of virus-infected
mice, and were consistent with the clinical symptoms and reached
peak levels when mice began to die. In addition, high levels of IL-
10, IFN-c and MCP-1 were also present in the virus-infected
mouse lungs, similar to observations found in severely affected
humans with 2009 H1N1 infection [38].
In summary, we successfully established an ARDS mouse model
induced by a virulent 2009 H1N1 variant, which demonstrated
key human ARDS clinical and pathological features, such as
respiratory distress, low PaO2, exudative, proliferative and fibrotic
lung, and high levels of inflammatory cells and cytokines. The
mouse model may contribute to the study of the pathogenesis and
therapy of ARDS induced by 2009 H1N1 virus.
Materials and Methods
Ethics statement
All animal research was approved by the Beijing Association for
Science and Technology (approval ID SYXK (Beijing) 2007-0023)
and complied with the guidelines of Beijing Laboratory Animal
Welfare and Ethics of the Beijing Administration Committee of
Laboratory Animals.
Viruses
The pandemic 2009 H1N1 virus, A/swine/Shandong/731/
2009 (SD/09), was isolated from swine in Shandong Province,
China, in December 2009. The complete genomic sequences for
this virus are available in the GenBank database under accession
numbers FJ951848–FJ951855. All the eight gene segments from
the swine isolate have a close relationship to 2009 H1N1 influenza
virus circulating in the human population and possess homologies
ARDS by 2009 H1N1 Variant in Mice
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strain A/California/04/2009. Virus stock was propagated in the
Madin–Darby canine kidney (MDCK) cells at 37uC for 48 h and
stored at 280uC for use in all the experiments. The titers of stock
viruses were determined by plaque assays in MDCK cells. To
determine LD50 of SD/09 virus, eight 6-week-old female BALB/c
mice per group were inoculated i.n. with 10
1–10
6 pfu (50 ml)
viruses and monitored for 14 days. The value of MLD50 was
calculated using the Spearman–Karber method and expressed by
pfu per MLD50 [39].
Experimental infections
We evaluated the pathogenicity of the virus in mice and found
that it could efficiently replicate in the lungs of mice with high
lethality (10
2.25 pfu per MLD50). To determine the optimal dose of
inoculation, 10 mice in each group were infected i.n. with 10
1.5,
10
2.5 or 10
3.5 pfu viruses, and the signs, body weight, and mortality
were monitored daily for each group for 14 days. Pilot experiments
indicated that a dose of 10
2.5 pfu was optimal, because the course
of the disease was prolonged and the mice presented with obvious
signs of respiratory illness.
BALB/c mice were lightly anesthetized and inoculated i.n. with
50 ml1 0
2.5 pfu SD/09 virus in PBS. Mock-infected animals were
inoculated i.n. with 50 ml PBS. At the indicated time, infected mice
were sacrificed, and the parameters that present the course of the
disease were determined. Twenty mice (10 infected with SD/09
virus and 10 inoculated with PBS) were used to investigate clinical
signs and mortality for 14 days.
Virus titration
Three mice were euthanized on days 2, 4, 6, 8, 10 and 14 p.i.
and their organs were collected. The collected tissues were
weighed, and 10% homogenates were prepared in cold PBS. The
homogenates were centrifuged at 3000 rpm for 10 min to remove
cell debris, and then the supernatants were 10-fold serially diluted
for viral titer determination by plaque assay in MDCK cells. Virus
titers were expressed as mean log pfu/g 6 standard deviation
(SD).
Assessment of lung water content
Three mice were euthanized on days 2, 4, 6, 8, 10 and 14 p.i.,
and the lungs were removed and weighed and then desiccated in
an oven at 60uC for 72 h. The lung wet weight:body weight ratio
and lung wet:dry weight ratio were calculated and used as an
indicator of lung edema, as previously described [40].
Histopathological examination
Three mice were euthanized on days 4, 6, 8 and 14 p.i. The
lungs were fixed in 10% buffered formalin, embedded in paraffin,
sectioned, and stained with hematoxylin and eosin. Lungs on day
14 p.i. were also stained with Masson’s trichrome.
Immunohistochemistry
Lung tissue sections taken on day 6 p.i. were stained for
influenza A virus antigens. An anti-influenza nucleoprotein
monoclonal antibody (AA5H; Abcam, Hong Kong) was used to
identify influenza A virus nucleoprotein in sections. Secondary
antibody (Millipore, Billerica, MA, USA) against the primary
antibody was labeled with horseradish peroxidase, and the color
reaction was developed with a horseradish peroxidase reaction kit
(diaminobenzidine- tetrahydrochloride; Sigma, St. Louis, MO,
USA).
Arterial blood gas analysis
Bloodgasanalysiswasperformed aspreviouslydescribed[13,41].
Three mice were anesthetized with Zoletil (tiletamine-zolazepam;
Virbac; 20 mg/g) on days 4, 6, 8, 10 and 14 p.i. Arterial blood
samples werewithdrawn intoa heparinizedsyringebypercutaneous
left ventricular sampling of lightly anesthetized mice that were
spontaneously breathing room air. Blood gas analysis was
immediately performed using a Vetstat Electrolyte and Blood Gas
Analyzer (Idexx laboratories, Westbrook, MA, USA).
Leukocyte counts in BALF
Leukocyte counts in BALF were performed as previously
described [42,43]. Briefly, three mice were euthanized on days
4, 6, 8 and 10 p.i., and the lungs were lavaged twice in situ with the
chest cavity opened by midline incision with a total volume of
1.0 ml saline (4uC) inserted through an endotracheal tube. The
rate of recovery of BALF was not less than 90% for all animals
tested. After the amount of fluid recovered was recorded, an
aliquot of BALF was diluted 1:1 with 0.01% crystal violet and
2.7% acetic acid for leukocyte staining and erythrocyte hemolysis.
The number of leukocytes in the BALF was counted with a
hemacytometer under a microscope. For differential counts, the
BALF samples from each mouse were stained with Wright stain,
and the numbers of monocytes, neutrophil and lymphocytes were
determined, on the basis of morphologic criteria, under a light
microscope, with evaluation of at least 200 cells per slide. All slides
were counted twice by different observers blinded to the status of
the animal.
Peripheral blood leukocyte counts
Heparinized blood samples were collected on days 4, 6, 8 and
10 p.i. The total numbers of leukocytes and differential blood
counts for three individual mice were analyzed using an
automated hematology analyzer.
Cytokine analysis in mouse lung
IL-6, IL-10, TNF, IFN-c and MCP-1 levels were determined in
lung homogenates using a cytometric bead array technique (BD
Cytometric BEAD Array Mouse Inflammation Kit; BD Biosci-
ence, San Diego, CA, USA) according to the manufacturer’s
instructions. Briefly, 50 ml mouse inflammation capture bead
suspension and 50 ml PE detection reagent were added to an equal
amount of sample standard dilution and incubated for 2 h at room
temperature in the dark. Subsequently, samples were washed by
adding 1 ml wash buffer and centrifugation at 2006 g at room
temperature for 5 min. Supernatants were discarded and 300 ml
wash buffer was added. Samples were analyzed on a BD
FACSArray bioanalyzer (BD Bioscience) according to the
manufacturer’s instructions. Standard curves were prepared
similar to the method above. Data were analyzed using BD
CBA Software (BD Bioscience). Finally, the chemokine or cytokine
levels were recorded as pg/ml homogenate.
Statistics
Data were analyzed by two-way analysis of variance using
GraphPad Prism version 5.00 (GraphPad Software, San Diego,
CA, USA). When a significant effect was observed, pairwise
comparisons were performed using the Bonferroni post-hoc test.
All data are reported as mean 6 SD.
Supporting Information
Figure S1 Body weight changes p.i. Mice were inoculated
i.n. with indicated doses of SD/09 viruses or PBS. Body weights
ARDS by 2009 H1N1 Variant in Mice
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p.i. to the initial weight is shown. Bars represent means 6 SD.
(TIF)
Video S1 Clinical symptoms of the mice infected with
SD/09 virus on day 8 p.i.
(MP4)
Video S2 Normal appearance of the mice inoculated
with PBS on day 8 p.i.
(MP4)
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